Best Life Sciences Companies in Hangzhou, China
The 91 best Life Sciences companies in Hangzhou, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ascletis.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Hangzhou
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascletis Developer of small molecules for the treatment of multiple diseases 42Funding top 19%Product top 30%Moat top 31%Innovation top 34% All 10 signals ▾Fundingtop 19% Producttop 30% Moattop 31% Innovationtop 34% Talentbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 36% Techbottom 30% Newsbottom 24% Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Product: 6 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 42/100 | $255M | 3 mo ago | Series B | Jinzi Wu Founder & CEO | 41 | PHPJW PlayerBootstrap+6 | — | — |
| 2 | Adlai Nortye Developer of immune oncolytic therapies for treating cancer | $253M | 59 mo ago | Public | Carsten Lu Founder & ceo | 27 27 → 63 (+133%) | — | 190 patents Targeted oncology therapeutics: small‑molecule degraders, kinase inhibitors, and antibody‑drug conjugates | — |
| 3 | Qixin Biotechnology Provider of gene-editing technology for therapies | $116M | 33 mo ago | Series A | Luhan Yang Co-Founder | — | Apple iCloud MailNode.jsVue.js+6 | — | — |
| 4 | Immorna Developer of mRNA-based therapeutics for cancer and other diseases 14Funding top 29%Moat top 38%Talent bottom 49%Global bottom 36% All 6 signals ▾Fundingtop 29% Moattop 38% Talentbottom 49% Globalbottom 36% Marketbottom 25% Techbottom 24% Funding: Raised $115M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 14/100 | $115M | 21 mo ago | Series A | Zihao Wang CEO | — | Microsoft ASP.NETBootstrapTengine+3 | — | — |
| 5 | PTM Biolab Developer of a technology platform for the discovery of biomarker, antibody, and proteomic analysis | $100M | 67 mo ago | Series B | Cheng Zhongyi CEO | 326 | — | 8 patents Epigenetic lysine PTM detection reagents and capecitabine polymer‑lipid nanocarrier delivery | — |
| 6 | Microtech Medical Medical devices developer for diabetes care | $88M | 66 mo ago | Public | — | 742 | BootstrapVideoJSGSAP+5 | 54 patents Closed-loop insulin delivery and continuous glucose monitoring biosensor technologies. | 1 partnership |
| 7 | Hangzhou Andao Pharmaceutical Developer of therapeutics for the treatment of cancer and kidney diseases | $85M | 53 mo ago | Series B | Liu Dong CEO | — | — | — | — |
| 8 | Ustar Biotechnologies Isothermal amplification kits for pathogen detection and genotyping of infectious diseases | $62M | 54 mo ago | Series E | — | 65 | WordPressMySQLPHP+21 | 31 patents Integrated microfluidic nucleic acid detection platforms for rapid CRISPR‑based diagnostics | — |
| 9 | Worg Developer of treatments for allergic and autoimmune diseases | $57M | 45 mo ago | Series B | — | 40 | Animate.cssBootstrapTengine+3 | — | — |
| 10 | Zenshine Pharmaceuticals Developer of small molecules drug for the treatment of cancer | $52M | 60 mo ago | Series A | Jinfu Yang Co-Founder | — | — | 20 patents Antiviral influenza agents and PI3Kα inhibitor therapeutics for oncology | — |
| 11 | Ranok Therapeutics Developer of novel therapeutics for the treatment of cancer | $50M | 58 mo ago | Series B | Weiwen Ying Founder & CEO | — | — | 77 patents KRAS G12D/G12V mutant inhibitors and targeted protein degradation therapeutics | — |
| 12 | Yunhu Technology Group Provider of DNA testing services | $38M | 81 mo ago | Series A | Chen Xiaobing CEO | 1,200 | — | 4 patents Minimally invasive surgical and injection devices for gastrointestinal and reconstructive procedures | — |
| 13 | Venus MedTech Transcatheter aortic valves | $37M | 97 mo ago | Public | Eric Zi Founder & CEO | 1,006 | PHPWindows ServerUIKit+6 | 354 patents Patents concentrated in health & consumer products | — |
| 14 | Chance Pharmaceuticals Developer of transformative inhalation therapies for pulmonology disorders 37Talent top 28%Funding top 41%Global bottom 38%Market bottom 37% All 5 signals ▾Talenttop 28% Fundingtop 41% Globalbottom 38% Marketbottom 37% Newsbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $31.0M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $31M | 15 mo ago | Series C | Peng Huang Co-Founder | — | — | — | — |
| 15 | RoboCT Technology Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions 50Funding top 36%Market top 42%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 36% Markettop 42% Growthtop 45% Talentbottom 49% Globalbottom 48% Techbottom 35% Funding: Raised $29.4M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Market: 100 employees (top 20% of Life Sciences) · Top-5,000,000 web property rank vs industry peers · Fliar Intelligence Index 50/100 | $29M | 3 mo ago | Series B | Wang Tian Founder & CEO | 100 | Cart FunctionalityPHPLayui+13 | — | 1 partnership |
| 16 | Hangzhou Lianchuan Biotechnology Provider of genetic testing services | $26M | 56 mo ago | Series B | — | 271 | — | — | — |
| 17 | Hangzhou Shuyang Biotechnology Developer of therapeutic antibodies and recombinant protein drugs | $20M | 46 mo ago | Series B | — | 180 | — | — | — |
| 18 | Zhejiang Norcong Neuroelectronics Developer of ear implant and speech processing devices | $16M | 68 mo ago | Series B | Chu Li CEO | — | WordPressMySQLPHP+8 | — | — |
| 19 | M20 Genomics Developer of single-cell products and related technologies | $15M | 49 mo ago | Seed | Yongcheng Wang Co-Founder & CTO | — | — | — | 2 launchs |
| 20 | Qiyuan Biological Developer of drugs for the treatment of autoimmune diseases 22Funding top 41%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 41% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 9 mo ago | Series B | Ding Shizhe CEO | — | — | — | — |
| 21 | Hangzhou Kaibao Biotechnology Developer of drugs for treating cancer | $14M | 71 mo ago | Series B | Sun Jianhua CEO | — | — | — | — |
| 22 | SynRx Therapeutics Developer of targeted cancer chemotherapy drugs | $14M | 43 mo ago | Seed | Xiaochun Yu Co-Founder | — | — | 18 patents Design and synthesis of fused nitrogen heterocycles as DNA repair enzyme inhibitors | — |
| 23 | Junhemeng Biopharmaceutical Developer of recombinant protein drugs for endocrine and metabolic fields | $14M | 25 mo ago | Series B | — | — | — | — | — |
| 24 | Celgenyx Developer of cellular immune products for the treatment of malignant tumors | $14M | 43 mo ago | Series A | Ken Ren CEO | — | — | — | — |
| 25 | Hangzhou Tongee Medical Technology Limited information available | $9M | 48 mo ago | Series B | — | 90 | — | — | — |
| 26 | Polymed Biopharmaceuticals Developer of small molecule therapeutics for cancer and autoimmune diseases | $8M | 58 mo ago | Seed | Jason Xiang Founder & CEO | — | — | 47 patents Patents concentrated in chemistry & materials | — |
| 27 | Medlinkbci Provider of brain-computer interface active rehabilitation device | $4M | 58 mo ago | Late Stage | — | 50 | — | — | — |
| 28 | Nanochap Bio-medical devices developer 69Talent top 35%Market top 39%Funding top 42%Global bottom 36% All 4 signals ▾Talenttop 35% Markettop 39% Fundingtop 42% Globalbottom 36% Talent: Analyst team rating 4/5 · 2 named leaders on record Market: 100 employees (top 25% of High Tech) rank vs industry peers · Fliar Intelligence Index 69/100 | $4M | 1 mo ago | Series B | Jiawei Yang Co-Founder & CEO | 100 | — | — | 1 job opening |
| 29 | Doouya Health management tools for infants | $2M | 131 mo ago | Deadpooled | Prasun Sarkar Founder & CEO | — | — | — | — |
Top 12 Life Sciences companies in Hangzhou
#1
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees$255Mraised▾
Developer of small molecules for the treatment of multiple diseases. It offers pipeline of drug candidates which include Ritonavir for Covid, Ravidasvir for HCV, ASC22 for HIV, ASC40 for NASH, acne, solid tumor, breast cancer, and others.
- Feb 2026Post IPO$107.9M
- Jan 2017Series B$100M
- Dec 2015Series B$20M
- Sep 2015Series B$35M
#2
Series B · Hangzhou, Zhejiang · founded 2017 · 100 employees$29.4Mraised▾
Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions. The company's products include exoskeleton robotics, robot joint modules, mecanum wheel modules, and servo motion control solutions. It also operate a rehabilitation cloud platform that supports remote rehabilitation guidance and a rehabilitation intelligence evaluation system that generates detailed assessment reports for users to track progress and effectiveness.
- Mar 2026Series B$13.7M
- Feb 2022Series A$15.7M
- Mar 2021Seed—
#3
Series B · Hangzhou, Zhejiang · founded 2014 · 100 employees$3.8Mraised▾
Nanochap is a bio-medical device developer. Some of its devices include neural stimulator, blood pressure measurement, portable pain relief management. The company has developed the NanoHug, blood pressure measuring device, uses the electronic blood pressure measurement technology. The device contains a sensor for measuring diastolic blood pressure, systolic blood pressure, heart rate, and the pulse image of the human body.
- May 2026Series B$43.9M
- Dec 2016Series A$3.8M
#4
Series B · Hangzhou, Zhejiang · founded 2020$14.5Mraised▾
Developer of drugs for the treatment of autoimmune diseases. The lead candidate of the company includes "QY101" a non-hormonal and non-steroidal anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor for Atopic dermatitis. Other drug candidates include QY211 for psoriasis, QY301 for ulcerative colitis, Crohn's disease, and QY401 for respiratory-related indications.
- Sep 2025Series B$28M
- Aug 2022Series A$14.5M
#5
Series A · Hangzhou, Zhejiang · founded 2019$115Mraised▾
Developer of mRNA-based therapeutics for cancer and other diseases. It offers mRNA delivery vehicles including polymers and lipid nanoparticles for intramuscular, intravenous, and tissue-targeting delivery. It has developed a pipeline for cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology.
- Aug 2024Grant (prize money)—
- Feb 2023Series A$100M
- Feb 2021Series A$15M
#6
Series C · Hangzhou, Zhejiang · founded 2015$31Mraised▾
Developer of transformative inhalation therapies for pulmonology disorders. The company's lead candidate CXF11 is a tiotropium bromide inhalation drug for the prevention of bronchospasm in patients with chronic obstructive pulmonary disease. Also, developing an inhaler to disperse powder and deliver particles to the lung.
- Mar 2025Series C—
- Jan 2022Series C—
- Oct 2021Series C$31M
#7
Series A · Hangzhou, Zhejiang · founded 2017$116Mraised▾
Provider of gene-editing technology for therapies. The company uses this platform of genetic engineering for developing tools for organ transplantation and regenerative medicines. It uses CRISPR/Cas9 system as a gene-editing tool.
- Sep 2023Series A$16M
- Mar 2021Series A$67M
- Sep 2019Series A$22.5M
- Jul 2018Series A$7.8M
#8
Public · Hangzhou, Zhejiang · founded 2014 · 27 employees$253Mraised▾
Developer of immune oncolytic therapies for treating cancer. The company's lead product, REOLYSIN is used for treating breast cancer. It selectively lyses tumors and activates the innate and adaptive immune systems. Other candidates of the company include AN0025 (for solid tumors), AN0015 & AN3005 (for multiple tumors).
- Jul 2021Series D$100M
- Aug 2020Series C$100M
- Jun 2018Series B$53M
#9
Series B · Hangzhou, Zhejiang$13.8Mraised▾
Developer of recombinant protein drugs for endocrine and metabolic fields
#10
Series B · Hangzhou, Zhejiang · founded 2014$85Mraised▾
Developer of therapeutics for the treatment of cancer and kidney diseases. The Companys lead oral small molecule compound AND017, which is used to treat anemia caused by chronic kidney disease. Other drug candidates include AND019 and AND021 for breast and kidney cancer.
- Dec 2021Series B$50M
- Jan 2019Series A$35M
#11
Series B · Hangzhou, Zhejiang · founded 2018 · 40 employees$57.5Mraised▾
Developer of treatments for allergic and autoimmune diseases. The company focuses on developing transformative immunotherapies based on two technology platforms, PCFiT and Apitope against allergic, autoimmune diseases, and other indications.
- Sep 2022Series B$57.5M
- Jan 2021Series A—
#12
Series E · Hangzhou, Zhejiang · founded 2005 · 65 employees$61.8Mraised▾
Isothermal amplification kits for pathogen detection and genotyping of infectious diseases. Its proprietary technologies include instrument-free nucleic acid extraction, isothermal amplification, and rapid DNA amplicon detection device which form two nucleic acid testing platforms for microbe detection and SNP/Mutation detection. It developed a series of isothermal amplification testing kits based on these two platforms for pathogen detection and genotyping for tuberculosis, sexually transmitted diseases, and HBV genotyping.
- Nov 2021Series E$47M
- Feb 2021Series E—
- Aug 2014Series B$11.3M
- 2012Series B—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Hangzhou is moving
A read on the academic research around Biotechnology in Hangzhou — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
Hangzhou Medical College and affiliated hospitals lead cautiously optimistic biotechnology research (stance 0.51), focusing predominantly on RNA modifications and cancer detection via biosensors, with 60 papers published since 2020.
- Hangzhou Medical College12
- Hangzhou Academy of Agricultural Sciences8
- Hangzhou First People\'s Hospital8
- Hangzhou Normal University8
- Changzhou University7
- Gene5
- Transcription factor4
- Gene silencing2
- RNA interference2
- Transcriptome2
- Apoptosis3
- Gene knockdown3
- Messenger RNA3
- Metabolomics3
- Podocyte2
- Resistance (ecology)2
- Aroma2
- Yeast2
- Tigecycline1
- Context (archaeology)1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.